Optimizing the implementation of future treatment using surrogate end-points

Breast Cancer Research

Volumn 10, Issue SUPPL. 4, 2008, Pages

  Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; FEMALE; HUMAN; METABOLISM;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KI-67 ANTIGEN;

EID: 60749110935     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2186     Document Type: Article

References (8)

1. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008, 17:303-340. 10.1177/0962280207082719, 17925313.
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, . ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. 10.1016/S0140-6736(02)09088-8, 12090977, ATAC Trialists' Group.
3. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, . IMPACT Trialists Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005, 11:951s-958s. IMPACT Trialists.
4. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G, . IMPACT Trialists Group Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170. 10.1093/jnci/djk020, 17228000, IMPACT Trialists Group.
5. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998, 48:107-116. 10.1023/A:1005933815809, 9596482.
6. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005, 23:2477-2492. 10.1200/JCO.2005.07.559, 15767642.
7. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822. 10.1200/JCO.2006.09.6578, 17679728.
8. Jones RL, Salter J, A'hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2008,